The study objective was to investigate the effect of the Consciousness Energy Treated test formulation on vital organs like bones, heart, liver, lungs and brain using various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Shirley Theresa Holmlund, Canada and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in six different cells. The Biofield Energy Treated Medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 115.6% and 53.3% restoration of viable cells at 10 and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + UT-TI group showed 113.5% and 73.5% restoration of cell viability at 0.1 and 1 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Furthermore, 101.1%, 829.8% and 698.9% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 97.9% and 69.7% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 50 µg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 58.2% in the BT-Med + BT-TI group at 1 µg/mL in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 67.4% (at 0.1 µg/mL), 80.4% (at 0.1 µg/mL) and 119.8% (at 10 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively compared to the untreated. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 57.6% and 82.5% in the BT-Med + UT-TI group at 25 and 63 µg/mL, respectively; while 123.9% at 10 µg/mL in the BT-Med + BT-TI group compared to untreated. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 53.6% and 59% in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL compared to the untreated. Serotonin level was significantly increased by 85.3% in the UT-Med + BT-TI and BT-Med + BT-TI groups at 0.1 µg/mL as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 245.9% and 211.5% at 10 and 50 µg/mL, respectively in the UT-Med + BT-TI group; while 174.3% (at 10 µg/mL) in the BT-Med + UT-TI group as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Energy Treated test formulation has significantly improved the bones, heart, liver, lungs and brain functional enzymes biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect^®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect^® can be used as a complementary and alternative therapy against several disorders such as heart attack, coronary artery disease, heart failure, arrhythmias, congenital heart disease, cardiomyopathy, Wilson disease, 

Keywords: Biofield energy treatment, The Trivedi effect^®, Cardiac health, Bone health, Liver health, VDR receptor, Lungs health, Brain health 

INTRODUCTION

Bones, heart, liver, lungs and brain disorders are the major concern of human overall health across the globe. The World Health Organization (WHO) estimates, in 2016, ~17.5 million people die due to cardiovascular (heart) disorders, ~3.5 million people die due to lungs disorders, ~1.3 million people die due to liver disorders around the globe each year [1]. Moreover, ~1.2 million people most frequently diagnosed adult-onset brain disorders in each year in the USA. [2]. Three main criteria to keep a healthy heart include the opening blood vessels, strengthening the heart muscle and controlling free radical damage by antioxidants [3]. The release of liver mitochondrial enzymes is considered strong evidence for hepatic (liver) necrosis, which is associated with an increased production of reactive oxygen species (ROS) that leads to hepatic lipid peroxidation [4-6]. Oxidative stress in the respiratory system increases the production of mediators of pulmonary inflammation and initiate or promote mechanisms of carcinogenesis [7]. The lung is one of the major organs, which is highly exposed by various oxidants, i.e., endogenous and exogenous oxidants (cigarette smoke, mineral dust, ozone and radiation). These oxidants produce free radicals, while reactive oxygen species (ROS) and reactive nitrogen species (RNS) are produced by phagocytes as well as by alveolar, polymorph nuclear, bronchial and different endothelial cells [8]. However, the role of oxidative stress in the pathogenesis of lung diseases has been widely reported such as asthma, chronic obstructive pulmonary disease (COPD), lung malignancies and parenchymal lung diseases like idiopathic pulmonary fibrosis and lung granulomatous diseases [9]. Serotonin (5-hydroxytryptamine, 5-HT) is among the brain’s neuromodulators responsible for behavior and understanding [10]. Apart from medicines, non-pharmacologic methods that can increase serotonin by increasing recognition and happiness and well-being. These factors can protect against mental and physical disorders [11]. There is currently no universally accepted test formulation, which improve the organ health biomarkers. With this respect, the novel test formulation was designed on the basis of best scientific literature, which is the combination of herbal products viz. Panax ginseng extract and beta carotene, minerals viz. calcium chloride, magnesium gluconate, zinc chloride, sodium selenate, ferrous sulfate, and vitamins viz. vitamin B12, vitamin D₃, ascorbic acid and vitamin B6. This formulation is designed for overall functioning of the organs that can results in improved overall health conditions against many pathological conditions such as lung disorder, liver disorder, breast cancer, liver cancer, aging, muscle damage, and overall health. Minerals and vitamins present in the test formulation provide significant functional support to all the vital organs [12-14]. In addition, Panax ginseng is one of the best reported medicinal plants that improve mental, physical abilities, cognitive health and is potent immuno modulator [15,16].

Various study data suggested the effect of Energy Therapy in cancer patients through therapeutic touch [17]; massage therapy [18], etc. Complementary and Alternative Medicine (CAM) therapies are preferred model of treatment, among which Biofield Therapy (or Healing Modalities) is one approach to enhance emotional, mental, physical and human wellness. The National Center of Complementary and Integrative Health (NCCIH) has recognized and allowed Biofield Energy Healing as a CAM approach in addition to other therapies and medicines such as natural products, chiropractic/osteopathic manipulation, Qi Gong, deep breathing, Tai Chi, yoga, meditation, massage, special diets, healing touch, relaxation techniques, traditional Chinese herbs and medicines, naturopathy, movement therapy, homeopathy, progressive relaxation, guided imagery, pilates, acupuncture, acupressure, Reiki, rolfing structural integration, hypnotherapy, Ayurvedic medicine, mindfulness, essential oils, aromatherapy, and cranial sacral therapy. The Human Biofield Energy has subtle energy that has the capacity to work in an effective manner [19]. CAM therapies have been practiced worldwide with reported clinical benefits in different health disease profiles [20]. This energy can be harnessed and transmitted by the practitioners into living and non-living things via the process of Biofield Energy Healing. The Biofield Energy Treatment, the Trivedi Effect^®, has been reported to have a significant impact in the field of cancer research [21,22], materials science [23,24], microbiology [25,26], agriculture [27,28], nutraceuticals [29,30] and biotechnology [31,32]. Further, the Trivedi Effect^® also significantly improved bioavailability of various low bioavailable compounds [33-35], an improved overall skin health [36,37], bone health [38-40], human health and wellness. Based on the excellent outcomes of the Biofield Energy Therapy in wide spectrum of areas, the authors intend to see the impact of the Biofield Energy Healing Treated test formulation on the function of vital organs such as bones, heart, liver, lungs and brain specific biomarkers in different cell-lines.

MATERIALS AND METHODS

Chemicals and reagents

Ferrous sulfate, vitamin B6, vitamin D₃, vitamin B12, calcium chloride, naringenin, trimetazidine (TMZ), 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT) and ethylenediaminetetraacetic acid (EDTA) were obtained from Sigma Chemical Co. (St. Louis, MO). Zinc chloride, magnesium gluconate, β-carotene and calcitriol were purchased from TCI chemicals, Japan. Panax ginseng extract obtained from Panacea Phytoextracts, India. Sodium selenate and ascorbic acid were obtained from Alfa Aesar, India. Silymarin and curcumin were obtained from Sanat Chemicals, India and quercetin obtained from Clearsynth, India. Reverse Transcription Kit, RNeasy Mini Kit and Syber Green PCR kits were procured from Quagen, India. All the other chemicals used in this experiment were analytical grade procured from India.

Biofield energy healing strategy

The test formulation was the combination of eleven ingredients viz. calcium chloride, Panax ginseng extract, vitamin B12, β-carotene, vitamin D₃, zinc chloride, magnesium gluconate, sodium selenate, ferrous sulfate, ascorbic acid and vitamin B6. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Shirley Theresa Holmlund, under laboratory conditions for ~3 min through healer’s unique Biofield Energy Transmission process and were labeled as the Biofield Energy Treated (BT) test formulation/media. Further, the untreated group was treated with a “sham” healer for comparison purposes. The “sham” healer did not have any knowledge about the Biofield Energy Healing Treatment. The Biofield Energy Healer was located in the Canada; however the test items were located in the research laboratory of Dabur Research Foundation, New Delhi, India. Biofield Energy Healer did not visit the laboratory, nor had any contact with the test samples. After that, the Biofield Energy Treated and untreated test items were kept in similar sealed conditions and used for the study as per the study plan.

Assessment of cell viability using MTT assay

Cells were counted using hemocytometer and plated in 96-well plates at the specific density described in Table 1. The cells were then incubated overnight under growth conditions to allow cell recovery and exponential growth. Following overnight incubation, cells were treated with different concentrations of test formulations (BT/UT). Following respective treatments, cells were incubated in a CO₂ incubator at 37°C, 5% CO₂ and 95% humidity and incubated for time period mentioned in Table 1. After incubation, the plates were taken out and 20 µL of 5 mg/mL of MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide solution was added to all the wells followed by additional incubation for 3 h at 37°C. The supernatant was aspirated and 150 µL of DMSO was added to each well to dissolve formazan crystals. The absorbance of each well was read at 540 nm using Synergy HT microplate reader. The percentage cytotoxicity at each tested concentration of TI was calculated using Equation 1:

% Cytotoxicity = [(R-X)/R] *100............ (1)

Where, X=Absorbance of treated cells; R=Absorbance of untreated cells

The concentrations exhibiting percentage cytotoxicity <30% was considered as non-cytotoxic [41].

Evaluation of the cytoprotective effect of the formulation

Cells (human cardiac fibroblasts-HCF; human hepatoma cells-HepG2; and adenocarcinomic human alveolar basal epithelial cells-A549) were counted and plated in suitable medium followed by overnight incubation. The cells were then treated with the test items/positive control at the non-cytotoxic concentrations for 24 h. After 24 h, oxidative stress was given to the cells using 10 mM t-BHP for 3.5 h. The untreated cells served as a control that did not receive any treatment and was maintained in cell growth medium only. Cells treated with 10 mM of t-BHP alone served as negative control. After 3.5 h of incubation with t-BHP the above plates were taken out and cell viability was determined by MTT assay. The percentage protection corresponding to each treatment was calculated using Equation 2:

% Protection = [(Absorbance_sample-Absorbance_t-BHP)]*100 / [Absorbance_untreated-Absorbance_{t_BHP}]............... (2)

Assessment of alkaline phosphatase (ALP) activity

The cells (human bone osteosarcoma cells-MG-63 and human endometrial adenocarcinoma cells-Ishikawa) were counted using a hemocytometer and plated in 24-well plates at the density corresponding to 1 × 10⁴ cells/well in phenol-free DMEM supplemented with 10% CD-FBS. Following the respective treatments, the cells in the above plate were incubated for 48 h in CO₂ incubator at 37°C, 5% CO₂ and 95% humidity. After 48 h of incubation, the plates were taken out and processed for the measurement of ALP enzyme activity. The cells were washed with 1x PBS and lysed by freeze-thaw method, i.e., incubation at -80°C for 20 min followed by incubation at 37°C for 10 min. To the lysed cells, 50 µL of substrate solution, i.e., 5 mm of p-nitrophenyl phosphate (pNPP) in 1 M diethanolamine and 0.24 mm magnesium chloride (MgCl₂) solution (pH 10.4) was added to all the wells followed by incubation for 1 h at 37°C. The absorbance of the above solution was read at 405 nm using Synergy HT microplate reader (Biotek, USA). The absorbance values obtained were normalized with substrate blank (pNPP solution alone) absorbance values. The percentage increase in ALP enzyme activity with respect to the untreated cells (baseline group) was calculated using Equation 3:

% Increase in ALP = {(X-R)/R}*100                   (3)

Where, X=Absorbance of cells corresponding to positive control and test groups; R=Absorbance of cells corresponding to baseline group (untreated cells)

Estimation of lactate dehydrogenase (LDH) in human cardiac fibroblasts (HCF)

The human cardiac fibroblasts (HCF) Cells were counted and plated at the density of 0.25 × 10⁶ cells/ well in 24-well plates in cardiac fibroblast specific medium followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations for 24 h. After 24 h, oxidative stress was given to the cells using 10 mM t-BHP for 3.5 h. The untreated cells were served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 10 mM of t-BHP alone served as the negative control. After 3.5 h of incubation with t-BHP the above plates were taken out and LDH activity was determined using LDH activity kit as per manufacturer’s instructions. The percent increase in LDH activity was calculated using Equation 4:

% Increase = [(LDH activity_sample-LDH activity_t-BHP)]*100 / [LDH activity_untreated-LDH activity_{t_BHP}].............. (4)

Estimation of ALT in liver cells (HepG2)

The human hepatoma cells (HepG2) were counted and plated at the density of 5 × 10⁴ cells/well in 48-well plates in DMEM media followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations for 24 h. After 24 h, oxidative stress was given to the cells using 400 µM t-BHP for 3.5 h. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 400 µM of t-BHP alone served as negative control. After 3.5 h of incubation with t-BHP the above plates were taken out and ALT activity was determined using ALT activity kit as per manufacturer’s instructions. The percent increase in ALT activity was calculated using Equation 5:

% Increase = [(ALT activity_sample-ALT activity_t-BHP)]*100/ [ALT activity_untreated-ALT activity_{t_BHP}]............. (5)

Estimation of superoxide dismutase (SOD) in lung (A549) cells

The adenocarcinomic human alveolar basal epithelial cells (A549) were counted and plated at the density of 1 × 10⁴ cells/well in 24-well plates in DMEM followed by overnight incubation. The cells were then treated with the test formulation/positive control at the non-cytotoxic concentrations along with 100 µM t-BHP to induce oxidative stress. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. Cells treated with 100 µM of t-BHP alone served as negative control. After 24 h of incubation with t-BHP the above plates were taken out and SOD activity was determined using SOD activity kit as per manufacturer’s instructions. The percent increase in SOD activity was calculated using Equation 6:

% Increase in SOD activity = ((X-R)/R)*100................ (6)

Where, X=SOD activity corresponding to test item or positive control; R=SOD activity corresponding to control group

Estimation of serotonin in neuronal cells (SH-SY5Y)

The human neuroblastoma (SH-SY5Y) cells were counted and plated at the density of 10 × 10⁴ cells/well in 96-well plates followed by overnight incubation. The cells were then treated with the test items/positive control at the non-cytotoxic concentrations. The untreated cells served as control that did not receive any treatment and were maintained in cell growth medium only. The treated cells were incubated for 24 h. Serotonin release was determined by ELISA as per manufacturer’s protocol. The percent increase in serotonin levels was calculated using Equation 7:

[(X-R)/R]*100................ (7)

Where, X=Serotonin levels corresponding to test item or positive control; R=Serotonin levels corresponding to control group

Effect of test formulation on vitamin D receptor (VDR) in bone (MG-63) cells

The human bone osteosarcoma (MG-63) cells were counted using the hemocytometer were plated at a density of 2 × 10⁵ cells/well in 6-well plates followed by overnight incubation. The cells were then sera starved for 24 h and treated with the test formulation/positive control at the non-cytotoxic concentrations. The untreated cells that served as control that did not receive any treatment and were maintained in cell growth medium only. The treated cells were incubated for 24 h and VDR expression was determined by Q-PCR using VDR specific primers. Cells were harvested by scrapping and washed with PBS. Cell pellets obtained were analyzed for VDR gene expression using human VDR specific primers: Forward: 5’-GCTGACCTGGTCAGTTACAGCA-3’, Reverse: 5’-CACGTCACTGACGCGGTACTT-3’. VDR gene expression was normalized using House-keeping (HK) reference. Relative quantification (RQ) of VDR gene in Biofield Energy Treated cells was calculated with respect to the untreated cells using Equation 8:

RQ = 2-N................ (8)

Where N is the relative Threshold Cycle (CT) value of treated sample with respect to the untreated sample

STATISTICAL ANALYSIS

All the values were represented as Mean ± SD (standard deviation) of three independent experiments. The statistical analysis was performed using SigmaPlot statistical software (v11.0). For two groups comparison student’s t-test was used. For multiple group comparison, one-way analysis of variance (ANOVA) was used followed by post-hoc analysis by Dunnett’s test. Statistically significant values were set at the level of p ≤ 0.05.

RESULTS AND DISCUSSION

Cell viability using MTT assay

Determination of non-cytotoxic concentration of the formulation and positive controls by MTT cell viability assay was used in terms of percent viable cells in six (6) different cell-lines viz. MG-63, Ishikawa, A549, HepG2, HCF and SH-SY5Y. Based on the percent cell viability data, it was observed that the formulation and positive controls were safe and non-toxic at the tested concentrations in six different cell lines and selected for other parameters analysis.

Evaluation of cytoprotective effect of the test formulation

The cytoprotective activity of the novel proprietary test formulation on vital organs like liver, heart and lungs was examined in in vitro cell-based assay under the stimulation of tert-butyl hydroperoxide (t-BHP) induced oxidative stress. t-BHP has been routinely used for the induction of oxidative stress in various cells [42]. The cytoprotective activity of the test formulation on the restoration of cell viability was determined against t-BHP induced cell damage and the result is shown in Figure 1. Trimetazidine (TMZ) was used as positive control in human cardiac fibroblasts cells (HCF) and showed, restoration of cell viability by 34.01%, 60.04% and 98.31% at 5, 10 and 25 µg/mL, respectively compared to the t-BHP induced group. Besides, the test formulation showed 52.7% restoration of cell viability at 1 µg/mL in the BT-Med + BT-TI group as compared to the UT-Med + UT-TI group. Moreover, at 10 µg/mL the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups showed 11.6%, 67.5% and 115.6% restoration of cell viability, respectively than UT-Med + UT-TI group. Additionally, the test formulation showed 41.9%, 62% and 71.8% restoration of cell viability at 25 µg/mL in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group. Further, at 63 µg/mL the test formulation showed 51.2% restoration of cell viability in the UT-Med + BT-TI group than UT-Med + UT-TI group (Figure 1). Silymarin was used as positive control in human hepatoma cells (HepG2) resulted, restoration of cell viability by 31.63%, 64.63% and 74.64% at 5, 10 and 25 µg/mL, respectively compared to the t-BHP induced group. The test formulation showed 113.5% restoration of cell viability at 0.1 µg/mL in the BT-Med + UT-TI group as compared to the UT-Med + UT-TI group. Moreover, at 1 µg/mL the BT-Med + UT-TI group showed 73.5% restoration of cell viability than UT-Med + UT-TI group. The test formulation showed 20.7% and 66.3% restoration of cell viability at 10 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group (Figure 1). Quercetin was used as positive control in adenocarcinomic human alveolar basal epithelial cells (A549) resulted, restoration of cell viability by 30.8%, 69.33% and 72.22% at 5, 10 and 25 µg/mL, respectively compared to the t-BHP induced group. Besides, the test formulation showed 60% restoration of cell viability at 1 µg/mL in the UT-Med + BT-TI group compared to the UT-Med + UT-TI group. Moreover, at 10 µg/mL the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups showed 101.1%, 829.8% and 698.9% restoration of cell viability, respectively than UT-Med + UT-TI group. Additionally, the test formulation showed 46.2% and 63.3% restoration of cell viability at 25 µg/mL in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group. Further, the test formulation showed 67.6% and 62.8% restoration of cell viability at 63 µg/mL in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the UT-Med + UT-TI group (Figure 1). Oxidative stress is linked with a wide variety of inflammatory and metabolic disease conditions. Besides, cumulative damage of cells by free radicals inadequately neutralized by antioxidants [43]. The study results suggest that Biofield Treatment has significantly protects t-BHP induced cardiotoxicity, hepatotoxicity and lung cell toxicity which could be due to The Trivedi Effect^®-Biofield Energy Healing as free radical scavenging activity. Therefore, Biofield Energy Healing Treatment could be used for the management of cardiovascular, liver and various lung disorders.

Effect of test formulation on serotonin in human neuroblastoma (SH-SY5Y) cells

The effect of test formulation on serotonin level is shown in Figure 6. The positive control showed 66.33%, 115.13% and 143.41% increase the level of serotonin. The level of serotonin was significantly increased by 33.3%, 85.3% and 85.3% in the UT-Med + BT-TI, BT-Med + UT-TI, BT-Med + BT-TI groups, respectively at 0.1 µg/mL compared to the UT-Med + UT-TI group. Moreover, at 1 µg/mL, 5-HT level was significantly increased by 21.9%, 7.7% and 74.2% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively as compared to the UT-Med + UT-TI group. Further, the serotonin level was significantly increased by 13.8%, 35.8% and 33.6% in the UT-Med + BT-TI, BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 10 µg/mL as compared to the UT-Med + UT-TI group (Figure 6). Serotonin (5-HT) is a neurotransmitter responsible for stress, anxiety, aggressive behavior, and many more [51]. Recent studies reported that brain endothelium is the specific target for serotonin and actively involved in the regulation of the blood-brain barrier (BBB) permeability and the cerebral blood flow via receptor-mediated mechanisms [52]. Thus, this experimental data suggested that Biofield Energy Healing Treated novel formulation significantly improved the serotonin level, which would be highly useful against various neurodegenerative diseases and other age-related disorders and improved the normal functioning of the brain tissues.

CONCLUSION

The study findings showed that the tested novel test formulation was safe and non-toxic based on the MTT cell viability assay in six tested cells. The treatment group like BT-Med + BT-TI showed 115.6% restoration of cell viability at 10 µg/mL in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + UT-TI group showed 113.5% and 73.5% restoration of cell viability at 0.1 and 1 µg/mL, respectively in human hepatoma cells (HepG2) compared to the untreated group. Additionally, 101.1%, 829.8%, and 698.9% restoration of cell viability at 10 µg/mL in adenocarcinomic human alveolar basal epithelial cells (A549) compared to the untreated group. Alkaline phosphatase (ALP) activity was significantly increased by 97.9% and 69.7% in the UT-Med + BT TI and BT-Med + BT TI groups, respectively at 50 µg/mL compared to the untreated in human bone osteosarcoma cells (MG-63). Moreover, ALP activity was significantly increased by 58.2% in the BT-Med + BT-TI group at 1 µg/mL than untreated group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 80.4% (at 0.1 µg/mL) and 119.8% (at 10 µg/mL) in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated group. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 82.5% (at 63 µg/mL) and 123.9% (at 10 µg/mL) in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated group. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 59% in the BT-Med + BT-TI group at 10 µg/mL compared to the untreated group. The serotonin level was significantly increased by 85.3% at 0.1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups as compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 245.9% and 211.5% at 10 and 50 µg/mL, respectively in the UT-Med + BT-TI group; while 174.3% (at 10 µg/mL) in the BT-Med + UT-TI group compared to the untreated group in MG-63 cells. In conclusion, The Biofield Energy Treatment significantly improved heart, liver, bones, neuronal and lungs functional enzymes biomarkers and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (peripheral artery disease, high blood pressure, congenital heart disease, stroke, congestive heart failure, rheumatic heart disease, carditis, valvular heart disease, thromboembolic disease and venous thrombosis, etc.), hepatic disorders (cirrhosis, Wilson disease, liver cancer, hemochromatosis), and lungs disorders (Asthma, Emphysema, Chronic bronchitis, Pneumonia, Cystic fibrosis). Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., liver, kidney, and heart transplants), aging, hormonal imbalance and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Dermatitis, Asthma, Ulcerative Colitis (UC), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Aplastic Anemia, Multiple Sclerosis, Hepatitis, Graves’ Disease, Irritable Bowel Syndrome (IBS), Dermatomyositis, Diabetes, Myasthenia Gravis, Atherosclerosis, Parkinson’s Disease, Systemic, etc., to Lupus Erythematosus (SLE), stress, improve overall health and Quality of Life.

ACKNOWLEDGEMENT

Authors gratefully acknowledged to Trivedi Global, Inc., Trivedi Science and Trivedi Master Wellness for their support. In addition, authors are thankful for the support of Dabur Research Foundation for conducting this study.

CONFLICT OF INTEREST

Authors declare no conflict of interest.

1.       Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2016 (GBD) (2016) Results. Seattle, United States: Institute for Health Metrics and Evaluation (IHME).

2.       Pal S (2018) Incidence and prevalence of major neurologic disorders. US Pharm 43: 24.

3.       Rakesh S, Arunporn I (2017) Herbal supplements or herbs in heart disease: Herbiceutical formulation, clinical trials, futuristic developments. J Cardiol Cardiovasc Ther 3: 555603.

4.       Contreras-Zentella ML, Hernández-Muñoz R (2016) Is liver enzyme release really associated with cell necrosis induced by oxidant stress? Oxid Med Cell Longev 2016: 3529149.

5.       Schmidt E, Schmidt FW (1970) Aspects of enzyme diagnosis. Med Welt 21: 805-816.

6.       Frederiks WM, Vogels IM, Fronik GM (1984) Plasma ornithine carbamyl transferase level as an indicator of ischaemic injury of rat liver. Cell Biochem Funct 2: 217-220.

7.       Boots AW, Haenen GR, Bast A (2003) Oxidant metabolism in chronic obstructive pulmonary disease. Eur Respir J 46: 14S-27S.

8.       Romieu I (2005) Nutrition and lung health. Int J Tuberc Lung Dis 9: 362-374.

9.       Kelly FJ (2005) Vitamins and respiratory disease: Antioxidant micronutrients in pulmonary health and disease. Proc Nutr Soc 64: 510-526.

10.    Fischer AG, Ullsperger M (2017) An update on the role of serotonin and its interplay with dopamine for reward. Front Hum Neurosci 11: 484.

11.    Anonymous (2006) A sensible 10 year plan for mental health. Lancet 367: 86.

12.    Ryan-Harshman M, Aldoori W (2005) Health benefits of selected minerals. Can Fam Physician 51: 673-675.

13.    Rayman MP (2000) The importance of selenium to human health. Lancet 356: 233-241.

14.    Beard JL, Connor JR (2003) Iron status and neural functioning. Ann Rev Nutr 23: 41-58.

15.    Coleman CI, Hebert JH, Reddy P (2003) The effects of Panax ginseng on quality of life. J Clin Pharm Ther 28: 5-15.

16.    Das L, Bhaumik E, Raychaudhuri U, Chakraborty R (2011) Role of nutraceuticals in human health. J Food Sci Technol 49: 173-183.

17.    Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, et al. (2010) Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun 24: 1231-1240.

18.    Ironson G, Field T, Scafidi F, Hashimoto M, Kumar M, et al. (1996) Massage therapy is associated with enhancement of the immune system's cytotoxic capacity. Int J Neurosci.84: 205-217.

19.    Jain S, Hammerschlag R, Mills P, Cohen L, Krieger R, et al. (2015) Clinical studies of biofield therapies: Summary, methodological challenges and recommendations. Glob Adv Health Med 4: 58-66.

20.    Rubik B (2002) The biofield hypothesis: Its biophysical basis and role in medicine. J Altern Complement Med 8: 703-717.

21.    Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) The potential impact of biofield treatment on human brain tumor cells: A time-lapse video microscopy. J Integr Oncol 4: 141.

22.    Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) In vitro evaluation of biofield treatment on cancer biomarkers involved in endometrial and prostate cancer cell lines. J Cancer Sci Ther 7: 253-257.

23.    Trivedi MK, Tallapragada RM (2008) A transcendental to changing metal powder characteristics. Met Powder Rep 63: 22-28, 31.

24.    Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O (2015) Studies of the atomic and crystalline characteristics of ceramic oxide nano powders after bio field treatment. Ind Eng Manage 4: 161.         

25.    Trivedi MK, Branton A, Trivedi D, Nayak G, Charan S, et al. (2015) Phenotyping and 16S rDNA analysis after biofield treatment on Citrobacter braakii: A urinary pathogen. J Clin Med Genomics 3: 129.

26.    Trivedi MK, Patil S, Shettigar H, Mondal SC, Jana S (2015) An impact of biofield treatment: Antimycobacterial susceptibility potential using BACTEC 460/MGIT-TB System. Mycobact Dis 5: 189.

27.    Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, et al. (2015) Morphological characterization, quality, yield and DNA fingerprinting of biofield energy treated alphonso mango (Mangifera indica L.). J Food Nutr Sci 3: 245-250.

28.    Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, et al. (2015) Evaluation of biochemical marker – Glutathione and DNA fingerprinting of biofield energy treated Oryza sativa. Am J Biosci 3: 243-248.

29.    Trivedi MK, Branton A, Trivedi D, Nayak G, Plikerd WD, et al. (2017) A Systematic study of the biofield energy healing treatment on physicochemical, thermal, structural and behavioral properties of magnesium gluconate. Int J Bioorg Chem 2: 135-145.

30.    Parulkar VR, Trivedi MK, Branton A, Trivedi D, Nayak G, et al. (2018) Improved metabolism of vitamin D₃ in human osteoblasts cells after biofield energy healing treatment. Am J Lab Med 3: 11-19.

31.    Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Phenotypic and biotypic characterization of Klebsiella oxytoca: An impact of biofield treatment. J Microbiol Biochem Technol 7: 203-206.

32.    Nayak G, Altekar N (2015) Effect of biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.

33.    Branton A, Jana S (2017) The influence of energy of consciousness healing treatment on low bioavailable resveratrol in male Sprague Dawley rats. Int J Clin Dev Anat 3: 9-15.

34.    Branton A, Jana S (2017) The use of novel and unique biofield energy healing treatment for the improvement of poorly bioavailable compound, berberine in male Sprague Dawley rats. Am J Clin Exp Med 5: 138-144.

35.    Branton A, Jana S (2017) Effect of The biofield energy healing treatment on the pharmacokinetics of 25-hydroxyvitamin D₃ [25(OH)D₃] in rats after a single oral dose of vitamin D₃. Am J Pharmacol Phytother 2: 11-18.

36.    Parulkar VR, Trivedi MK, Branton A, Trivedi D, Nayak G, et al. (2017) The use of consciousness energy healing based herbomineral formulation for skin anti-aging strategies. J Food Nutr Sci 5: 96-106.

37.    Singh J, Trivedi MK, Branton A, Trivedi D, Nayak G, et al. (2017) Consciousness energy healing treatment based herbomineral formulation: A safe and effective approach for skin health. Am J Pharmacol Phytother 2: 1-10.

38.    Anagnos D, Trivedi K, Branton A, Trivedi D, Nayak G, et al. (2018) Influence of biofield treated vitamin D₃ on proliferation, differentiation and maturation of bone-related parameters in MG-63 cell-line. Int J Biomed Eng Clin Sci 4: 6-14.

39.    Lee AC, Trivedi K, Branton A, Trivedi D, Nayak G, et al. (2018) The potential benefits of biofield energy treated vitamin D₃ on bone mineralization in human bone osteosarcoma cells (MG-63). Int J Nutr Food Scis 7: 30-38.

40.    Stutheit ME, Trivedi K, Branton A, Trivedi D, Nayak G, et al. (2018) Biofield energy treated vitamin D₃: Therapeutic implication on bone health using osteoblasts cells. Am J Life Sci 6: 13-21.

41.    Alía M, Ramos S, Mateos R, Bravo L, Goya L (2005) Response of the antioxidant defense system to tert-butyl hydroperoxide and hydrogen peroxide in a human hepatoma cell line (HepG2). J Biochem Mol Toxicol 19: 119-128.

42.    Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, Esquivel-Soto J, Esquivel-Chirino C, et al. (2014) Hepatoprotective effect of silymarin. World J Hepatol 6: 144-149.

43.    Noeman SA, Hamooda HE, Baalash AA (2011) Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. Diabetol Metab Syndr 3: 17.

44.    Kyd PA, De Vooghtl K, Kerkhoff F, Thomas E, Fairneyl A (1998) Clinical usefulness of bone alkaline phosphatase in osteoporosis. Ann Clin Biochem 35: 717-725.

45.    Randall DC, Jones DL (1997) Eliminating unnecessary lactate dehydrogenase testing: A utilization review study and national survey. Arch Intern Med 14: 1441-1444.

46.    Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, et al. (2011) Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2. Blood 117: 4696-4700.

47.    Giannini EG, Testa R, Savarino V (2005) Liver enzyme alteration: A guide for clinicians. CMAJ. 172: 367-379.

48.    Mathiesen U, Franzen L, Fryden A, Foberg U, Bodemar G (1999) The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol 34: 85-91.

49.    Weydert CJ, Cullen JJ (2010) Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc 5: 51-66.

50.    Autor AP, Frank L, Roberts RJ (1976) Developmental characteristics of pulmonary superoxide dismutase: Relationship to idiopathic respiratory distress syndrome. Pediatr Res 10: 154-158.

51.    Dorszewska J, Prendecki M, Oczkowska A, Rozycka A, Lianeri M, et al. (2013) Polymorphism of the COMT, MAO, DAT, NET and 5-HTT genes and biogenic amines in Parkinson’s disease. Curr Genomics 14: 518-533.

52.    Brust P, Friedrich A, Krizbai IA, Bergmann R, Roux F, et al. (2000) Functional expression of the serotonin transporter in immortalized rat brain micro vessel endothelial cells. J Neurochem 74: 1241-1248.

53.    Khosla S (2001) The OPG/RANKL/RANK system. Endocrinology 142: 5050-5055.

54.    Bouillon R (2001) Vitamin D: from photosynthesis, metabolism, and action to clinical applications. In: De Groot L, Jameson JL, Burger HG, editors. Endocrinology. 3^rd Edn. Saunders; Philadelphia, USA, pp: 1009-1028.

Holick MF (2006) Resurrection of vitamin D deficiency and rickets. J Clin Invest 116: 2062-2072.